AC IMMUNE SA SF-02 (F:IMR) — Stock Price

€1.96 EUR
▲ 1.66% today

AC IMMUNE SA SF-02 (F:IMR) is currently trading at €1.96 EUR, up 1.66% today. Over the past 52 weeks, shares have ranged between €1.67 and €3.32. This page tracks AC IMMUNE SA SF-02's live share price on the F exchange, its daily price and volume history, and — where reported — its income statement, balance sheet, cash flow statement, and earnings history. For company valuation and market capitalisation context, see IMR market cap.

AC IMMUNE SA SF-02 (IMR) Stock Price Chart — Daily History & Trading Volume

The chart below tracks AC IMMUNE SA SF-02's daily closing share price and trading volume on the F exchange over the past year, giving a clear view of recent price momentum and liquidity.

AC IMMUNE SA SF-02 Income Statement — Revenue, Profit & Earnings by Year

AC IMMUNE SA SF-02's annual income statement shows how revenue converts into profit each fiscal year, including gross profit, operating income, EBITDA, and net income.

Fiscal Year 20252024202320222021
Total Revenue €3.57 Million €27.31 Million €14.80 Million €3.94 Million €0.00
Cost of Revenue
Gross Profit
Research & Development €56.44 Million €62.57 Million €54.61 Million €60.34 Million €62.28 Million
SG&A €11.65 Million €11.43 Million €10.58 Million €9.58 Million €10.88 Million
Total Operating Expenses €72.44 Million €79.69 Million €68.42 Million €74.78 Million €79.01 Million
Operating Income €-68.86 Million €-52.38 Million €-53.62 Million €-70.85 Million €-79.01 Million
EBITDA
EBIT
Interest Expense €191.00K €133.00K €176.00K €355.00K €581.00K
Income Before Tax €-70.45 Million €-50.91 Million €-54.22 Million €-70.74 Million €-72.99 Million
Income Tax Expense
Net Income €-70.45 Million €-50.92 Million €-54.23 Million €-70.75 Million €-73.00 Million

AC IMMUNE SA SF-02 Balance Sheet — Assets, Liabilities & Shareholder Equity

The balance sheet below summarizes AC IMMUNE SA SF-02's financial position at each fiscal year-end — what it owns (assets), what it owes (liabilities), and the resulting shareholder equity.

Fiscal Year 20252024202320222021
Total Assets €154.25 Million €230.91 Million €182.81 Million €185.94 Million €261.44 Million
Total Current Assets €96.72 Million €171.99 Million €125.15 Million €128.09 Million €202.63 Million
Cash & Equivalents
Short-term Investments €64.62 Million €129.21 Million €24.55 Million €91.00 Million €116.00 Million
Net Receivables €0.00 €14.80 Million €0.00
Inventory
Property, Plant & Equipment
Goodwill
Total Liabilities €109.37 Million €118.64 Million €22.17 Million €16.95 Million €29.46 Million
Total Current Liabilities €94.69 Million €100.84 Million €13.58 Million €11.48 Million €20.03 Million
Long-term Debt
Net Debt
Total Stockholder Equity €44.88 Million €112.27 Million €160.64 Million €168.99 Million €231.98 Million
Retained Earnings €-439.02 Million €-368.24 Million €-316.20 Million €-264.01 Million €-200.94 Million

AC IMMUNE SA SF-02 Cash Flow Statement — Operating, Investing & Financing Activities

This cash flow statement breaks down how AC IMMUNE SA SF-02 generates and spends cash across operating, investing, and financing activities each fiscal year, including free cash flow and capital expenditures.

Fiscal Year 20252024202320222021
Operating Cash Flow €-69.26 Million €65.84 Million €-60.41 Million €-73.57 Million €-65.69 Million
Capital Expenditures €900.00K €576.00K €801.00K €1.24 Million €2.63 Million
Free Cash Flow €-70.16 Million €65.27 Million €-61.21 Million €-74.81 Million €-68.32 Million
Investing Cash Flow
Financing Cash Flow €-1.02 Million €-1.12 Million €43.25 Million €-1.35 Million €40.75 Million
Dividends Paid
Stock-Based Compensation €4.40 Million €5.47 Million €4.37 Million €3.33 Million €4.13 Million
Depreciation €2.50 Million €2.16 Million €2.21 Million €2.36 Million €2.41 Million
Change in Cash €-6.74 Million €-40.57 Million €48.49 Million €-51.15 Million €-78.61 Million

AC IMMUNE SA SF-02 Earnings History — EPS Actual vs. Analyst Estimates

Track AC IMMUNE SA SF-02's quarterly earnings per share (EPS) against Wall Street estimates, along with the earnings surprise percentage for each reporting period.

Report Date EPS Actual EPS Estimate Surprise
Aug 04, 2026 -0.11
Apr 29, 2026 -0.14
Mar 12, 2026 -0.17
Nov 04, 2025 -0.17
Aug 04, 2025
Apr 30, 2025
Mar 12, 2025
Nov 04, 2024